Loading...
XNAS
YMAB
Market cap197mUSD
Jul 11, Last price  
4.36USD
1D
-3.54%
1Q
-9.73%
IPO
-83.83%
Name

Y-mAbs Therapeutics Inc

Chart & Performance

D1W1MN
P/E
P/S
2.25
EPS
Div Yield, %
Shrs. gr., 5y
4.73%
Rev. gr., 5y
0.00%
Revenues
88m
+3.38%
000020,750,00034,897,00065,267,00084,819,00087,685,000
Net income
-30m
L+38.45%
-17,057,000-19,161,000-43,274,000-78,886,000-118,343,000-56,345,000-96,325,000-21,427,000-29,666,000
CFO
-16m
L-42.30%
-11,166,000-15,870,000-41,229,000-73,497,000-91,231,000-102,556,000-75,921,000-27,232,000-15,714,000
Earnings
Aug 11, 2025

Profile

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
IPO date
Sep 21, 2018
Employees
147
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
87,685
3.38%
84,819
29.96%
65,267
87.03%
Cost of revenue
64,241
65,635
99,139
Unusual Expense (Income)
NOPBT
23,444
19,184
(33,872)
NOPBT Margin
26.74%
22.62%
Operating Taxes
(146)
561
757
Tax Rate
2.92%
NOPAT
23,590
18,623
(34,629)
Net income
(29,666)
38.45%
(21,427)
-77.76%
(96,325)
70.96%
Dividends
Dividend yield
Proceeds from repurchase of equity
100
84
BB yield
-0.03%
-0.04%
Debt
Debt current
630
1,804
868
Long-term debt
1,010
1,936
2,666
Deferred revenue
Other long-term liabilities
4,012
6,239
3,052
Net debt
(65,594)
(74,897)
(102,228)
Cash flow
Cash from operating activities
(15,714)
(27,232)
(75,921)
CAPEX
Cash from investing activities
Cash from financing activities
4,311
100
84
FCF
30,310
5,180
(31,283)
Balance
Cash
67,234
78,637
105,762
Long term investments
Excess cash
62,850
74,396
102,499
Stockholders' equity
(484,868)
(457,017)
(434,708)
Invested Capital
581,704
566,562
548,748
ROIC
4.11%
3.34%
ROCE
24.21%
17.51%
EV
Common stock shares outstanding
44,329
43,645
43,704
Price
7.83
14.81%
6.82
39.75%
4.88
-69.90%
Market cap
347,096
16.61%
297,662
39.57%
213,274
-69.53%
EV
281,502
222,765
111,046
EBITDA
23,979
19,919
(33,033)
EV/EBITDA
11.74
11.18
Interest
757
Interest/NOPBT